| 
        
        
              
                |  2006/04/01 | 
               
               
                | AJCN - Vitamin D3 supplementation reduced inflammatory markers in patients with congestive heart failure    | 
               
               
                
                    Schleithoff SS, Zittermann A, Tenderich G, et al.  Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr, 2006; 83 (4):754-759.  
                    | 
               
              
                Background: Elevated circulating concentrations of proinflammatory cytokines may contribute to the pathogenesis of congestive heart failure (CHF). In vitro studies suggest that vitamin D suppresses proinflammatory cytokines and increases antiinflammatory cytokines.  
 
Objective: We evaluated the effect of vitamin D supplementation on the survival rate and different biochemical variables in patients with CHF.  
 
Design: One hundred twenty-three patients randomly received either 50 µg vitamin D3/d plus 500 mg Ca/d [D(+) group] or placebo plus 500 mg Ca/d [D(-) group] for 9 mo. Biochemical variables were assessed at baseline and after 9 mo. The survival rate was calculated for a follow-up period of 15 mo.  
 
Results: Ninety-three patients completed the study. Significant treatment effects were observed on logarithmic-transformed serum concentrations of 25-hydroxyvitamin D (P = 0.001), parathyroid hormone (P = 0.007), tumor necrosis factor  (P = 0.006), and interleukin 10 (P = 0.042). 25-Hydroxyvitamin D increased by 26.8 ng/mL in the D(+) group but increased only by 3.6 ng/mL in the D(-) group.  
 
Compared with baseline, parathyroid hormone was significantly lower and the antiinflammatory cytokine interleukin 10 was significantly higher in the D(+) group after 9 mo. The proinflammatory cytokine tumor necrosis factor  increased in the D(-) group but remained constant in the D(+) group. The survival rate did not differ significantly between the study groups during the follow-up period.  
 
Conclusions: Vitamin D3 reduces the inflammatory milieu in CHF patients and might serve as a new antiinflammatory agent for the future treatment of the disease.  
 
Our data provide evidence for the involvement of an impaired vitamin D-parathyroid hormone axis in the progression of CHF.  
 | 
               
              
                | Source: 
				American Journal of Clinical Nutrition 								 | 
               
 
        
                   
                        |